Crizotinib (Xalkori) is now available through the PBS for lung cancer patients with a c-ROS proto-oncogene 1 (ROS1) gene rearrangement. From 1 January the drug is subsidised for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer. And from 1 February, osimertinib (Tagrisso) will be listed on the PBS for ...
Already a member?
Enter your email to keep reading.